Comparative Pharmacology
Head-to-head clinical analysis: EXKIVITY versus JASCAYD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXKIVITY versus JASCAYD.
EXKIVITY vs JASCAYD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible tyrosine kinase inhibitor that selectively targets epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, and specifically inhibits EGFR T790M and C797S resistance mutations, with less activity against wild-type EGFR.
JASCAYD (tasquinimod) is a selective allosteric inhibitor of S100A9, which binds to toll-like receptor 4 (TLR4) and receptor for advanced glycation end-products (RAGE). It modulates the tumor microenvironment by inhibiting myeloid-derived suppressor cell (MDSC) recruitment and function, reducing angiogenesis, and enhancing anti-tumor immune responses.
150 mg orally once daily with or without food.
Adults: 300 mg orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 48 hours, supporting once-daily dosing for systemic exposure.
Terminal elimination half-life is 12-15 hours; clinically relevant for once-daily dosing.
Primarily hepatic metabolism with biliary excretion; 91% of total recovered in feces (30% as unchanged drug), <1% in urine.
Primarily renal excretion (80%) as unchanged drug; 20% fecal via biliary elimination.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor